Manipal Hospitals Sarjapur Road hosted a session on HoLEP for Benign Prostatic Hyperplasia. This innovative technique, led by ...

PRNewswire Bangalore Karnataka [India] January 15 Manipal Hospitals Sarjapur Road recently hosted an awareness session on ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with ...

Winter leads to an increased risk of problems related to the prostate gland in seniors. Cold weather causes urinary and ...

MarinHealth Medical Center (MHMC) announced today that its surgeons have performed the first Aquablation procedures to treat ...

and conclude that their findings suggest the potential for such personalization in patients with BPH.

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

We are excited to reach this important milestone in the Expander-2 Pivotal Trial,” said Paul Edwards, President and CEO of Prodeon Medical. “Completing enrollment is a key step in our mission to ...

Dr. Niti Navanimitkul, MD, from the Urology Center at Bangkok Hospital Pattaya gave an informative presentation to the ...

A budget impact analysis was conducted based on a Markov decision model for the treatment of moderate to severe BPH comparing DUT + TAM FDC combination therapy over tamsulosin monotherapy.

How your doctor treats you depends on your age, health, the size of your prostate, and how BPH affects you. If your symptoms don't bother you too much, you can put off treatment and see how you feel.